A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A phase 3 trial testing Setidegrasib in pancreatic ductal adenocarcinoma, now recruiting.
Overview
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer is a phase 3 interventional study registered as NCT07409272, led by Astellas Pharma Global Development, and recruiting when checked on 2026-09-11. Official title: A Phase 3, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma. Planned enrolment is 614 participants (estimated). The study started in 2026-02-17 and primary completion is expected in 2029-08-31. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Shares Setidegrasib, Astellas and the tag ctgov-ingest.
- TrialA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Shares Astellas and the tag ctgov-ingest.
- TrialA Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialStudy of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.